Suven to test new drug for Alzheimer's and Schizophrenia

New Delhi, July 12 (UNI) Hyderabad-based Suven Life Sciences Ltd today said it has submitted an application with Drug Controller General of India for grant of permission to undertake Phase-1 clinical trials for their investigational New Drug (IND), SUVN-502.

SUVN-502 is novel, potent, safe, highly selective and orally active antagonist at a central nervous system serotonin receptor site 5-HTs intended for the treatment of cognitive disorders such as Alzheimer's and Schizophrenia, a statement said.

Treatment for Alzheimer's disease and Schizophrenia is an unmet medical need. The company's primary focus is to discover drugs that address significant unmet medical needs, the statement added.

UNI